Bone Therapeutics
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more
Market Cap & Net Worth: Bone Therapeutics (0R55)
Bone Therapeutics (LSE:0R55) has a market capitalization of $18.50K (€18.02K) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #43525 globally and #725 in its home market, demonstrating a -8.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bone Therapeutics's stock price €0.00 by its total outstanding shares 7834950 (7.83 Million).
Bone Therapeutics Market Cap History: 2026 to 2026
Bone Therapeutics's market capitalization history from 2026 to 2026. Data shows growth from $18.50K to $18.50K (0.00% CAGR).
Bone Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bone Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0R55 by Market Capitalization
Companies near Bone Therapeutics in the global market cap rankings as of March 18, 2026.
Key companies related to Bone Therapeutics by market ranking:
- TF665 (SA:TF665): Ranked #43516 globally with a market cap of $24.33K USD ( R$148.19K BRL).
- Central Pharmaceutical JSC No3 (VN:DP3): Ranked #43517 globally with a market cap of $24.31K USD ( ₫617.74 Million VND).
- LREN3F (SA:LREN3F): Ranked #43526 globally with a market cap of $24.11K USD ( R$146.85K BRL).
- Altitude International Holdings Inc (PINK:ALTD): Ranked #43527 globally with a market cap of $24.11K USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #43516 | TF665 | SA:TF665 | $24.33K | R$15.00 |
| #43517 | Central Pharmaceutical JSC No3 | VN:DP3 | $24.31K | ₫62600.00 |
| #43526 | LREN3F | SA:LREN3F | $24.11K | R$15.18 |
| #43527 | Altitude International Holdings Inc | PINK:ALTD | $24.11K | $0.00 |
Bone Therapeutics Historical Marketcap From 2026 to 2026
Between 2026 and today, Bone Therapeutics's market cap moved from $18.50K to $ 18.50K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €18.50K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bone Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.50K USD |
| MoneyControl | $18.50K USD |
| MarketWatch | $18.50K USD |
| marketcap.company | $18.50K USD |
| Reuters | $18.50K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.